# Gilead Sciences quarterly revenue

entity: /record/gilead-sciences.md  
predicate: quarterly_revenue  
page: /record/gilead-sciences/quarterly_revenue  
as_of: 2026-11-09  
cite: AsOf. "Gilead Sciences quarterly revenue: 8,300,000,000 United States dollar", as of 2026-09-30. Claim clm_64E20B8C7E0A, https://asof.is/claim/clm_64E20B8C7E0A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.  

As of November 9, 2026, Gilead Sciences's quarterly revenue on the AsOf record is $8.3 billion, dated September 30, 2026, from a primary source (sec.gov).

56 claims on Gilead Sciences's quarterly revenue, 1 open and 55 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted.

## Current quarterly revenue

What the record asserts on 2026-11-09.

- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 8,300,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_64E20B8C7E0A](/claim/clm_64E20B8C7E0A.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm

## Every dated value

One claim per line, oldest first. Superseded claims stay visible.

- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 1,278,125,000 United States dollar | valid 2008-06-30 to 2008-09-30 | conf 0.95 | superseded | superseded_by [clm_B6FDE1DA7495](/claim/clm_B6FDE1DA7495.md) | [clm_226CF11D49AD](/claim/clm_226CF11D49AD.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 1,371,268,000 United States dollar | valid 2008-09-30 to 2009-03-31 | conf 0.95 | superseded | superseded_by [clm_6C439F1205CB](/claim/clm_6C439F1205CB.md) | [clm_B6FDE1DA7495](/claim/clm_B6FDE1DA7495.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 1,530,460,000 United States dollar | valid 2009-03-31 to 2009-06-30 | conf 0.95 | superseded | superseded_by [clm_409B6A3263EA](/claim/clm_409B6A3263EA.md) | [clm_6C439F1205CB](/claim/clm_6C439F1205CB.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 1,647,155,000 United States dollar | valid 2009-06-30 to 2009-09-30 | conf 0.95 | superseded | superseded_by [clm_6A5B983F30CE](/claim/clm_6A5B983F30CE.md) | [clm_409B6A3263EA](/claim/clm_409B6A3263EA.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 1,801,389,000 United States dollar | valid 2009-09-30 to 2010-03-31 | conf 0.95 | superseded | superseded_by [clm_94692F85C62C](/claim/clm_94692F85C62C.md) | [clm_6A5B983F30CE](/claim/clm_6A5B983F30CE.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,085,853,000 United States dollar | valid 2010-03-31 to 2010-06-30 | conf 0.95 | superseded | superseded_by [clm_5442C3CA182A](/claim/clm_5442C3CA182A.md) | [clm_94692F85C62C](/claim/clm_94692F85C62C.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 1,927,224,000 United States dollar | valid 2010-06-30 to 2010-09-30 | conf 0.95 | superseded | superseded_by [clm_E81E791E414C](/claim/clm_E81E791E414C.md) | [clm_5442C3CA182A](/claim/clm_5442C3CA182A.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 1,937,656,000 United States dollar | valid 2010-09-30 to 2011-03-31 | conf 0.95 | superseded | superseded_by [clm_1391B52ED0E7](/claim/clm_1391B52ED0E7.md) | [clm_E81E791E414C](/claim/clm_E81E791E414C.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 1,926,094,000 United States dollar | valid 2011-03-31 to 2011-06-30 | conf 0.95 | superseded | superseded_by [clm_25328C0EEB54](/claim/clm_25328C0EEB54.md) | [clm_1391B52ED0E7](/claim/clm_1391B52ED0E7.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,137,253,000 United States dollar | valid 2011-06-30 to 2011-09-30 | conf 0.95 | superseded | superseded_by [clm_014BF0FFC36B](/claim/clm_014BF0FFC36B.md) | [clm_25328C0EEB54](/claim/clm_25328C0EEB54.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,121,660,000 United States dollar | valid 2011-09-30 to 2012-03-31 | conf 0.95 | superseded | superseded_by [clm_EB005128324C](/claim/clm_EB005128324C.md) | [clm_014BF0FFC36B](/claim/clm_014BF0FFC36B.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,282,449,000 United States dollar | valid 2012-03-31 to 2012-06-30 | conf 0.95 | superseded | superseded_by [clm_FB8DA58174AA](/claim/clm_FB8DA58174AA.md) | [clm_EB005128324C](/claim/clm_EB005128324C.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,405,186,000 United States dollar | valid 2012-06-30 to 2012-09-30 | conf 0.95 | superseded | superseded_by [clm_B8600EE329E3](/claim/clm_B8600EE329E3.md) | [clm_FB8DA58174AA](/claim/clm_FB8DA58174AA.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,426,597,000 United States dollar | valid 2012-09-30 to 2013-03-31 | conf 0.95 | superseded | superseded_by [clm_CF7263DF8433](/claim/clm_CF7263DF8433.md) | [clm_B8600EE329E3](/claim/clm_B8600EE329E3.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,531,635,000 United States dollar | valid 2013-03-31 to 2013-06-30 | conf 0.95 | superseded | superseded_by [clm_D79BF1F1049A](/claim/clm_D79BF1F1049A.md) | [clm_CF7263DF8433](/claim/clm_CF7263DF8433.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,767,394,000 United States dollar | valid 2013-06-30 to 2013-09-30 | conf 0.95 | superseded | superseded_by [clm_ED3CDE5E3ED7](/claim/clm_ED3CDE5E3ED7.md) | [clm_D79BF1F1049A](/claim/clm_D79BF1F1049A.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 2,782,833,000 United States dollar | valid 2013-09-30 to 2014-03-31 | conf 0.95 | superseded | superseded_by [clm_890094891137](/claim/clm_890094891137.md) | [clm_ED3CDE5E3ED7](/claim/clm_ED3CDE5E3ED7.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 4,998,956,000 United States dollar | valid 2014-03-31 to 2014-06-30 | conf 0.95 | superseded | superseded_by [clm_9B9748234060](/claim/clm_9B9748234060.md) | [clm_890094891137](/claim/clm_890094891137.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,534,943,000 United States dollar | valid 2014-06-30 to 2014-09-30 | conf 0.95 | superseded | superseded_by [clm_DF1ED50540CF](/claim/clm_DF1ED50540CF.md) | [clm_9B9748234060](/claim/clm_9B9748234060.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,041,832,000 United States dollar | valid 2014-09-30 to 2015-03-31 | conf 0.95 | superseded | superseded_by [clm_4B94008EAEAA](/claim/clm_4B94008EAEAA.md) | [clm_DF1ED50540CF](/claim/clm_DF1ED50540CF.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,594,000,000 United States dollar | valid 2015-03-31 to 2015-06-30 | conf 0.95 | superseded | superseded_by [clm_B77960C40400](/claim/clm_B77960C40400.md) | [clm_4B94008EAEAA](/claim/clm_4B94008EAEAA.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 8,244,000,000 United States dollar | valid 2015-06-30 to 2015-09-30 | conf 0.95 | superseded | superseded_by [clm_1FCA56C9FDDA](/claim/clm_1FCA56C9FDDA.md) | [clm_B77960C40400](/claim/clm_B77960C40400.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 8,295,000,000 United States dollar | valid 2015-09-30 to 2016-03-31 | conf 0.95 | superseded | superseded_by [clm_78CFE1D6629B](/claim/clm_78CFE1D6629B.md) | [clm_1FCA56C9FDDA](/claim/clm_1FCA56C9FDDA.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,794,000,000 United States dollar | valid 2016-03-31 to 2016-06-30 | conf 0.95 | superseded | superseded_by [clm_CC9217F333A8](/claim/clm_CC9217F333A8.md) | [clm_78CFE1D6629B](/claim/clm_78CFE1D6629B.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,776,000,000 United States dollar | valid 2016-06-30 to 2016-09-30 | conf 0.95 | superseded | superseded_by [clm_E2545AE7F426](/claim/clm_E2545AE7F426.md) | [clm_CC9217F333A8](/claim/clm_CC9217F333A8.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,500,000,000 United States dollar | valid 2016-09-30 to 2017-03-31 | conf 0.95 | superseded | superseded_by [clm_2C565010AFA4](/claim/clm_2C565010AFA4.md) | [clm_E2545AE7F426](/claim/clm_E2545AE7F426.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,505,000,000 United States dollar | valid 2017-03-31 to 2017-06-30 | conf 0.95 | superseded | superseded_by [clm_36D2C5AC16C0](/claim/clm_36D2C5AC16C0.md) | [clm_2C565010AFA4](/claim/clm_2C565010AFA4.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,141,000,000 United States dollar | valid 2017-06-30 to 2017-09-30 | conf 0.95 | superseded | superseded_by [clm_5093D8587F37](/claim/clm_5093D8587F37.md) | [clm_36D2C5AC16C0](/claim/clm_36D2C5AC16C0.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,512,000,000 United States dollar | valid 2017-09-30 to 2018-03-31 | conf 0.95 | superseded | superseded_by [clm_60A396F25E49](/claim/clm_60A396F25E49.md) | [clm_5093D8587F37](/claim/clm_5093D8587F37.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 5,088,000,000 United States dollar | valid 2018-03-31 to 2018-06-30 | conf 0.95 | superseded | superseded_by [clm_F8567009A977](/claim/clm_F8567009A977.md) | [clm_60A396F25E49](/claim/clm_60A396F25E49.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 5,648,000,000 United States dollar | valid 2018-06-30 to 2018-09-30 | conf 0.95 | superseded | superseded_by [clm_1F83C4577253](/claim/clm_1F83C4577253.md) | [clm_F8567009A977](/claim/clm_F8567009A977.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 5,596,000,000 United States dollar | valid 2018-09-30 to 2019-03-31 | conf 0.95 | superseded | superseded_by [clm_E4C5A9D23585](/claim/clm_E4C5A9D23585.md) | [clm_1F83C4577253](/claim/clm_1F83C4577253.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 5,281,000,000 United States dollar | valid 2019-03-31 to 2019-06-30 | conf 0.95 | superseded | superseded_by [clm_57A874E5A2DF](/claim/clm_57A874E5A2DF.md) | [clm_E4C5A9D23585](/claim/clm_E4C5A9D23585.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 5,685,000,000 United States dollar | valid 2019-06-30 to 2019-09-30 | conf 0.95 | superseded | superseded_by [clm_EF8E4AC29278](/claim/clm_EF8E4AC29278.md) | [clm_57A874E5A2DF](/claim/clm_57A874E5A2DF.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 5,604,000,000 United States dollar | valid 2019-09-30 to 2020-03-31 | conf 0.95 | superseded | superseded_by [clm_6E06E702C841](/claim/clm_6E06E702C841.md) | [clm_EF8E4AC29278](/claim/clm_EF8E4AC29278.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 5,548,000,000 United States dollar | valid 2020-03-31 to 2020-06-30 | conf 0.95 | superseded | superseded_by [clm_1ACA29BAAAE0](/claim/clm_1ACA29BAAAE0.md) | [clm_6E06E702C841](/claim/clm_6E06E702C841.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 5,143,000,000 United States dollar | valid 2020-06-30 to 2020-09-30 | conf 0.95 | superseded | superseded_by [clm_5E833A6DE889](/claim/clm_5E833A6DE889.md) | [clm_1ACA29BAAAE0](/claim/clm_1ACA29BAAAE0.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,577,000,000 United States dollar | valid 2020-09-30 to 2021-03-31 | conf 0.95 | superseded | superseded_by [clm_C2B19AF3DC0B](/claim/clm_C2B19AF3DC0B.md) | [clm_5E833A6DE889](/claim/clm_5E833A6DE889.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,423,000,000 United States dollar | valid 2021-03-31 to 2021-06-30 | conf 0.95 | superseded | superseded_by [clm_62C48A7DBB68](/claim/clm_62C48A7DBB68.md) | [clm_C2B19AF3DC0B](/claim/clm_C2B19AF3DC0B.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,217,000,000 United States dollar | valid 2021-06-30 to 2021-09-30 | conf 0.95 | superseded | superseded_by [clm_19619F47A018](/claim/clm_19619F47A018.md) | [clm_62C48A7DBB68](/claim/clm_62C48A7DBB68.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,421,000,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_43A0A904B6D6](/claim/clm_43A0A904B6D6.md) | [clm_19619F47A018](/claim/clm_19619F47A018.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,590,000,000 United States dollar | valid 2022-03-31 to 2022-06-30 | conf 0.95 | superseded | superseded_by [clm_DAC30FE4D631](/claim/clm_DAC30FE4D631.md) | [clm_43A0A904B6D6](/claim/clm_43A0A904B6D6.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,260,000,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_FB8452B2152F](/claim/clm_FB8452B2152F.md) | [clm_DAC30FE4D631](/claim/clm_DAC30FE4D631.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,042,000,000 United States dollar | valid 2022-09-30 to 2023-03-31 | conf 0.95 | superseded | superseded_by [clm_2124B66E70B5](/claim/clm_2124B66E70B5.md) | [clm_FB8452B2152F](/claim/clm_FB8452B2152F.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,352,000,000 United States dollar | valid 2023-03-31 to 2023-06-30 | conf 0.95 | superseded | superseded_by [clm_1E9F69BD5141](/claim/clm_1E9F69BD5141.md) | [clm_2124B66E70B5](/claim/clm_2124B66E70B5.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,599,000,000 United States dollar | valid 2023-06-30 to 2023-09-30 | conf 0.95 | superseded | superseded_by [clm_56E2DDB08CBD](/claim/clm_56E2DDB08CBD.md) | [clm_1E9F69BD5141](/claim/clm_1E9F69BD5141.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,051,000,000 United States dollar | valid 2023-09-30 to 2024-03-31 | conf 0.95 | superseded | superseded_by [clm_C8DA722C3664](/claim/clm_C8DA722C3664.md) | [clm_56E2DDB08CBD](/claim/clm_56E2DDB08CBD.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,686,000,000 United States dollar | valid 2024-03-31 to 2024-06-30 | conf 0.95 | superseded | superseded_by [clm_18BCC2F491A8](/claim/clm_18BCC2F491A8.md) | [clm_C8DA722C3664](/claim/clm_C8DA722C3664.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,954,000,000 United States dollar | valid 2024-06-30 to 2024-09-30 | conf 0.95 | superseded | superseded_by [clm_39562DEC6D14](/claim/clm_39562DEC6D14.md) | [clm_18BCC2F491A8](/claim/clm_18BCC2F491A8.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,545,000,000 United States dollar | valid 2024-09-30 to 2025-03-31 | conf 0.95 | superseded | superseded_by [clm_4E922360F385](/claim/clm_4E922360F385.md) | [clm_39562DEC6D14](/claim/clm_39562DEC6D14.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,667,000,000 United States dollar | valid 2025-03-31 to 2025-06-30 | conf 0.95 | superseded | superseded_by [clm_E0FB0CBAE021](/claim/clm_E0FB0CBAE021.md) | [clm_4E922360F385](/claim/clm_4E922360F385.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,082,000,000 United States dollar | valid 2025-06-30 to 2025-09-30 | conf 0.95 | superseded | superseded_by [clm_3A5203A42518](/claim/clm_3A5203A42518.md) | [clm_E0FB0CBAE021](/claim/clm_E0FB0CBAE021.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,769,000,000 United States dollar | valid 2025-09-30 to 2026-03-31 | conf 0.95 | superseded | superseded_by [clm_5B00A751741D](/claim/clm_5B00A751741D.md) | [clm_3A5203A42518](/claim/clm_3A5203A42518.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 6,960,000,000 United States dollar | valid 2026-03-31 to 2026-06-30 | conf 0.95 | superseded | superseded_by [clm_2C725370A4DF](/claim/clm_2C725370A4DF.md) | [clm_5B00A751741D](/claim/clm_5B00A751741D.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 7,803,000,000 United States dollar | valid 2026-06-30 to 2026-09-30 | conf 0.95 | superseded | superseded_by [clm_64E20B8C7E0A](/claim/clm_64E20B8C7E0A.md) | [clm_2C725370A4DF](/claim/clm_2C725370A4DF.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm
- [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 8,300,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_64E20B8C7E0A](/claim/clm_64E20B8C7E0A.md)
  sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm

## What replaced what

- $1.28 billion (2008-06-30 to 2008-09-30, [clm_226CF11D49AD](/claim/clm_226CF11D49AD.md)) was replaced by $1.37 billion from 2008-09-30 ([clm_B6FDE1DA7495](/claim/clm_B6FDE1DA7495.md))
- $1.37 billion (2008-09-30 to 2009-03-31, [clm_B6FDE1DA7495](/claim/clm_B6FDE1DA7495.md)) was replaced by $1.53 billion from 2009-03-31 ([clm_6C439F1205CB](/claim/clm_6C439F1205CB.md))
- $1.53 billion (2009-03-31 to 2009-06-30, [clm_6C439F1205CB](/claim/clm_6C439F1205CB.md)) was replaced by $1.65 billion from 2009-06-30 ([clm_409B6A3263EA](/claim/clm_409B6A3263EA.md))
- $1.65 billion (2009-06-30 to 2009-09-30, [clm_409B6A3263EA](/claim/clm_409B6A3263EA.md)) was replaced by $1.8 billion from 2009-09-30 ([clm_6A5B983F30CE](/claim/clm_6A5B983F30CE.md))
- $1.8 billion (2009-09-30 to 2010-03-31, [clm_6A5B983F30CE](/claim/clm_6A5B983F30CE.md)) was replaced by $2.09 billion from 2010-03-31 ([clm_94692F85C62C](/claim/clm_94692F85C62C.md))
- $2.09 billion (2010-03-31 to 2010-06-30, [clm_94692F85C62C](/claim/clm_94692F85C62C.md)) was replaced by $1.93 billion from 2010-06-30 ([clm_5442C3CA182A](/claim/clm_5442C3CA182A.md))
- $1.93 billion (2010-06-30 to 2010-09-30, [clm_5442C3CA182A](/claim/clm_5442C3CA182A.md)) was replaced by $1.94 billion from 2010-09-30 ([clm_E81E791E414C](/claim/clm_E81E791E414C.md))
- $1.94 billion (2010-09-30 to 2011-03-31, [clm_E81E791E414C](/claim/clm_E81E791E414C.md)) was replaced by $1.93 billion from 2011-03-31 ([clm_1391B52ED0E7](/claim/clm_1391B52ED0E7.md))
- $1.93 billion (2011-03-31 to 2011-06-30, [clm_1391B52ED0E7](/claim/clm_1391B52ED0E7.md)) was replaced by $2.14 billion from 2011-06-30 ([clm_25328C0EEB54](/claim/clm_25328C0EEB54.md))
- $2.14 billion (2011-06-30 to 2011-09-30, [clm_25328C0EEB54](/claim/clm_25328C0EEB54.md)) was replaced by $2.12 billion from 2011-09-30 ([clm_014BF0FFC36B](/claim/clm_014BF0FFC36B.md))
- $2.12 billion (2011-09-30 to 2012-03-31, [clm_014BF0FFC36B](/claim/clm_014BF0FFC36B.md)) was replaced by $2.28 billion from 2012-03-31 ([clm_EB005128324C](/claim/clm_EB005128324C.md))
- $2.28 billion (2012-03-31 to 2012-06-30, [clm_EB005128324C](/claim/clm_EB005128324C.md)) was replaced by $2.41 billion from 2012-06-30 ([clm_FB8DA58174AA](/claim/clm_FB8DA58174AA.md))
- $2.41 billion (2012-06-30 to 2012-09-30, [clm_FB8DA58174AA](/claim/clm_FB8DA58174AA.md)) was replaced by $2.43 billion from 2012-09-30 ([clm_B8600EE329E3](/claim/clm_B8600EE329E3.md))
- $2.43 billion (2012-09-30 to 2013-03-31, [clm_B8600EE329E3](/claim/clm_B8600EE329E3.md)) was replaced by $2.53 billion from 2013-03-31 ([clm_CF7263DF8433](/claim/clm_CF7263DF8433.md))
- $2.53 billion (2013-03-31 to 2013-06-30, [clm_CF7263DF8433](/claim/clm_CF7263DF8433.md)) was replaced by $2.77 billion from 2013-06-30 ([clm_D79BF1F1049A](/claim/clm_D79BF1F1049A.md))
- $2.77 billion (2013-06-30 to 2013-09-30, [clm_D79BF1F1049A](/claim/clm_D79BF1F1049A.md)) was replaced by $2.78 billion from 2013-09-30 ([clm_ED3CDE5E3ED7](/claim/clm_ED3CDE5E3ED7.md))
- $2.78 billion (2013-09-30 to 2014-03-31, [clm_ED3CDE5E3ED7](/claim/clm_ED3CDE5E3ED7.md)) was replaced by $5 billion from 2014-03-31 ([clm_890094891137](/claim/clm_890094891137.md))
- $5 billion (2014-03-31 to 2014-06-30, [clm_890094891137](/claim/clm_890094891137.md)) was replaced by $6.53 billion from 2014-06-30 ([clm_9B9748234060](/claim/clm_9B9748234060.md))
- $6.53 billion (2014-06-30 to 2014-09-30, [clm_9B9748234060](/claim/clm_9B9748234060.md)) was replaced by $6.04 billion from 2014-09-30 ([clm_DF1ED50540CF](/claim/clm_DF1ED50540CF.md))
- $6.04 billion (2014-09-30 to 2015-03-31, [clm_DF1ED50540CF](/claim/clm_DF1ED50540CF.md)) was replaced by $7.59 billion from 2015-03-31 ([clm_4B94008EAEAA](/claim/clm_4B94008EAEAA.md))
- $7.59 billion (2015-03-31 to 2015-06-30, [clm_4B94008EAEAA](/claim/clm_4B94008EAEAA.md)) was replaced by $8.24 billion from 2015-06-30 ([clm_B77960C40400](/claim/clm_B77960C40400.md))
- $8.24 billion (2015-06-30 to 2015-09-30, [clm_B77960C40400](/claim/clm_B77960C40400.md)) was replaced by $8.3 billion from 2015-09-30 ([clm_1FCA56C9FDDA](/claim/clm_1FCA56C9FDDA.md))
- $8.3 billion (2015-09-30 to 2016-03-31, [clm_1FCA56C9FDDA](/claim/clm_1FCA56C9FDDA.md)) was replaced by $7.79 billion from 2016-03-31 ([clm_78CFE1D6629B](/claim/clm_78CFE1D6629B.md))
- $7.79 billion (2016-03-31 to 2016-06-30, [clm_78CFE1D6629B](/claim/clm_78CFE1D6629B.md)) was replaced by $7.78 billion from 2016-06-30 ([clm_CC9217F333A8](/claim/clm_CC9217F333A8.md))
- $7.78 billion (2016-06-30 to 2016-09-30, [clm_CC9217F333A8](/claim/clm_CC9217F333A8.md)) was replaced by $7.5 billion from 2016-09-30 ([clm_E2545AE7F426](/claim/clm_E2545AE7F426.md))
- $7.5 billion (2016-09-30 to 2017-03-31, [clm_E2545AE7F426](/claim/clm_E2545AE7F426.md)) was replaced by $6.51 billion from 2017-03-31 ([clm_2C565010AFA4](/claim/clm_2C565010AFA4.md))
- $6.51 billion (2017-03-31 to 2017-06-30, [clm_2C565010AFA4](/claim/clm_2C565010AFA4.md)) was replaced by $7.14 billion from 2017-06-30 ([clm_36D2C5AC16C0](/claim/clm_36D2C5AC16C0.md))
- $7.14 billion (2017-06-30 to 2017-09-30, [clm_36D2C5AC16C0](/claim/clm_36D2C5AC16C0.md)) was replaced by $6.51 billion from 2017-09-30 ([clm_5093D8587F37](/claim/clm_5093D8587F37.md))
- $6.51 billion (2017-09-30 to 2018-03-31, [clm_5093D8587F37](/claim/clm_5093D8587F37.md)) was replaced by $5.09 billion from 2018-03-31 ([clm_60A396F25E49](/claim/clm_60A396F25E49.md))
- $5.09 billion (2018-03-31 to 2018-06-30, [clm_60A396F25E49](/claim/clm_60A396F25E49.md)) was replaced by $5.65 billion from 2018-06-30 ([clm_F8567009A977](/claim/clm_F8567009A977.md))
- $5.65 billion (2018-06-30 to 2018-09-30, [clm_F8567009A977](/claim/clm_F8567009A977.md)) was replaced by $5.6 billion from 2018-09-30 ([clm_1F83C4577253](/claim/clm_1F83C4577253.md))
- $5.6 billion (2018-09-30 to 2019-03-31, [clm_1F83C4577253](/claim/clm_1F83C4577253.md)) was replaced by $5.28 billion from 2019-03-31 ([clm_E4C5A9D23585](/claim/clm_E4C5A9D23585.md))
- $5.28 billion (2019-03-31 to 2019-06-30, [clm_E4C5A9D23585](/claim/clm_E4C5A9D23585.md)) was replaced by $5.69 billion from 2019-06-30 ([clm_57A874E5A2DF](/claim/clm_57A874E5A2DF.md))
- $5.69 billion (2019-06-30 to 2019-09-30, [clm_57A874E5A2DF](/claim/clm_57A874E5A2DF.md)) was replaced by $5.6 billion from 2019-09-30 ([clm_EF8E4AC29278](/claim/clm_EF8E4AC29278.md))
- $5.6 billion (2019-09-30 to 2020-03-31, [clm_EF8E4AC29278](/claim/clm_EF8E4AC29278.md)) was replaced by $5.55 billion from 2020-03-31 ([clm_6E06E702C841](/claim/clm_6E06E702C841.md))
- $5.55 billion (2020-03-31 to 2020-06-30, [clm_6E06E702C841](/claim/clm_6E06E702C841.md)) was replaced by $5.14 billion from 2020-06-30 ([clm_1ACA29BAAAE0](/claim/clm_1ACA29BAAAE0.md))
- $5.14 billion (2020-06-30 to 2020-09-30, [clm_1ACA29BAAAE0](/claim/clm_1ACA29BAAAE0.md)) was replaced by $6.58 billion from 2020-09-30 ([clm_5E833A6DE889](/claim/clm_5E833A6DE889.md))
- $6.58 billion (2020-09-30 to 2021-03-31, [clm_5E833A6DE889](/claim/clm_5E833A6DE889.md)) was replaced by $6.42 billion from 2021-03-31 ([clm_C2B19AF3DC0B](/claim/clm_C2B19AF3DC0B.md))
- $6.42 billion (2021-03-31 to 2021-06-30, [clm_C2B19AF3DC0B](/claim/clm_C2B19AF3DC0B.md)) was replaced by $6.22 billion from 2021-06-30 ([clm_62C48A7DBB68](/claim/clm_62C48A7DBB68.md))
- $6.22 billion (2021-06-30 to 2021-09-30, [clm_62C48A7DBB68](/claim/clm_62C48A7DBB68.md)) was replaced by $7.42 billion from 2021-09-30 ([clm_19619F47A018](/claim/clm_19619F47A018.md))
- $7.42 billion (2021-09-30 to 2022-03-31, [clm_19619F47A018](/claim/clm_19619F47A018.md)) was replaced by $6.59 billion from 2022-03-31 ([clm_43A0A904B6D6](/claim/clm_43A0A904B6D6.md))
- $6.59 billion (2022-03-31 to 2022-06-30, [clm_43A0A904B6D6](/claim/clm_43A0A904B6D6.md)) was replaced by $6.26 billion from 2022-06-30 ([clm_DAC30FE4D631](/claim/clm_DAC30FE4D631.md))
- $6.26 billion (2022-06-30 to 2022-09-30, [clm_DAC30FE4D631](/claim/clm_DAC30FE4D631.md)) was replaced by $7.04 billion from 2022-09-30 ([clm_FB8452B2152F](/claim/clm_FB8452B2152F.md))
- $7.04 billion (2022-09-30 to 2023-03-31, [clm_FB8452B2152F](/claim/clm_FB8452B2152F.md)) was replaced by $6.35 billion from 2023-03-31 ([clm_2124B66E70B5](/claim/clm_2124B66E70B5.md))
- $6.35 billion (2023-03-31 to 2023-06-30, [clm_2124B66E70B5](/claim/clm_2124B66E70B5.md)) was replaced by $6.6 billion from 2023-06-30 ([clm_1E9F69BD5141](/claim/clm_1E9F69BD5141.md))
- $6.6 billion (2023-06-30 to 2023-09-30, [clm_1E9F69BD5141](/claim/clm_1E9F69BD5141.md)) was replaced by $7.05 billion from 2023-09-30 ([clm_56E2DDB08CBD](/claim/clm_56E2DDB08CBD.md))
- $7.05 billion (2023-09-30 to 2024-03-31, [clm_56E2DDB08CBD](/claim/clm_56E2DDB08CBD.md)) was replaced by $6.69 billion from 2024-03-31 ([clm_C8DA722C3664](/claim/clm_C8DA722C3664.md))
- $6.69 billion (2024-03-31 to 2024-06-30, [clm_C8DA722C3664](/claim/clm_C8DA722C3664.md)) was replaced by $6.95 billion from 2024-06-30 ([clm_18BCC2F491A8](/claim/clm_18BCC2F491A8.md))
- $6.95 billion (2024-06-30 to 2024-09-30, [clm_18BCC2F491A8](/claim/clm_18BCC2F491A8.md)) was replaced by $7.55 billion from 2024-09-30 ([clm_39562DEC6D14](/claim/clm_39562DEC6D14.md))
- $7.55 billion (2024-09-30 to 2025-03-31, [clm_39562DEC6D14](/claim/clm_39562DEC6D14.md)) was replaced by $6.67 billion from 2025-03-31 ([clm_4E922360F385](/claim/clm_4E922360F385.md))
- $6.67 billion (2025-03-31 to 2025-06-30, [clm_4E922360F385](/claim/clm_4E922360F385.md)) was replaced by $7.08 billion from 2025-06-30 ([clm_E0FB0CBAE021](/claim/clm_E0FB0CBAE021.md))
- $7.08 billion (2025-06-30 to 2025-09-30, [clm_E0FB0CBAE021](/claim/clm_E0FB0CBAE021.md)) was replaced by $7.77 billion from 2025-09-30 ([clm_3A5203A42518](/claim/clm_3A5203A42518.md))
- $7.77 billion (2025-09-30 to 2026-03-31, [clm_3A5203A42518](/claim/clm_3A5203A42518.md)) was replaced by $6.96 billion from 2026-03-31 ([clm_5B00A751741D](/claim/clm_5B00A751741D.md))
- $6.96 billion (2026-03-31 to 2026-06-30, [clm_5B00A751741D](/claim/clm_5B00A751741D.md)) was replaced by $7.8 billion from 2026-06-30 ([clm_2C725370A4DF](/claim/clm_2C725370A4DF.md))
- $7.8 billion (2026-06-30 to 2026-09-30, [clm_2C725370A4DF](/claim/clm_2C725370A4DF.md)) was replaced by $8.3 billion from 2026-09-30 ([clm_64E20B8C7E0A](/claim/clm_64E20B8C7E0A.md))

## Questions this record answers

### What is Gilead Sciences's current quarterly revenue?

$8.3 billion, dated September 30, 2026, from a primary source (sec.gov). The record asserts this claim as of November 9, 2026 (status valid, confidence 0.95).

### When did Gilead Sciences's quarterly revenue last change?

The latest value on the record is $8.3 billion, dated September 30, 2026; before it the record holds $7.8 billion, dated June 30, 2026 and closed on September 30, 2026.

### What was Gilead Sciences's quarterly revenue before $8.3 billion?

$7.8 billion, valid from June 30, 2026 to September 30, 2026 (status superseded), from a primary source (sec.gov).


## Read on

- This page: /record/gilead-sciences/quarterly_revenue (markdown: /record/gilead-sciences/quarterly_revenue.md)
- Entity twin: /record/gilead-sciences.md · timeline: /timelines/gilead-sciences.md
- Every company's quarterly revenue: /facts/quarterly_revenue.md

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.